Clinical Trial Update: An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a new daily subcutaneous formulation of glatiramer acetate for relapsing-remitting multiple sclerosis was terminated; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2014-04-02